Emtricitabine/Rilpivirine/Tenofovir Alafenamide
- TRADE NAME: Odefsey (Gilead)
- INDICATIONS: HIV-1 infection
- CLASS: Hepatitis B virus necleoside analog reverse transcriptase inhibitor (tenofovir alafenamide), Non-nucleoside reverse transcriptase inhibitor (rilpivirine), Nucleoside analog reverse transcriptase inhibitor (emtricitabine)
- HALF-LIFE: 10 hours (emtricitabine); 50 hours (rilpivirine); <1 hour (tenofovir alafenamide)
FDA APPROVAL DATE: 03/01/2016
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Carbamazepine, Dexamethasone, Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Oxcarbazepine, Pantoprazole, Phenobarbital, Phenytoin, Rabeprazole, Rifampin, Rifapentine, St John's Wort
PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk
LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
RENAL.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric